Heparin and Derivatives for Advanced Cell Therapies
Heparin and its derivatives are saving thousands of human lives annually, by successfully preventing and treating thromboembolic events. Although the mode of action during anticoagulation is well studied, their influence on cell behavior is not fully understood as is the risk of bleeding and other s...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/21/12041 |
| _version_ | 1797512388955602944 |
|---|---|
| author | Sandra Laner-Plamberger Michaela Oeller Eva Rohde Katharina Schallmoser Dirk Strunk |
| author_facet | Sandra Laner-Plamberger Michaela Oeller Eva Rohde Katharina Schallmoser Dirk Strunk |
| author_sort | Sandra Laner-Plamberger |
| collection | DOAJ |
| description | Heparin and its derivatives are saving thousands of human lives annually, by successfully preventing and treating thromboembolic events. Although the mode of action during anticoagulation is well studied, their influence on cell behavior is not fully understood as is the risk of bleeding and other side effects. New applications in regenerative medicine have evolved supporting production of cell-based therapeutics or as a substrate for creating functionalized matrices in biotechnology. The currently resurgent interest in heparins is related to the expected combined anti-inflammatory, anti-thrombotic and anti-viral action against COVID-19. Based on a concise summary of key biochemical and clinical data, this review summarizes the impact for manufacturing and application of cell therapeutics and highlights the need for discriminating the different heparins. |
| first_indexed | 2024-03-10T06:01:07Z |
| format | Article |
| id | doaj.art-d718155f4c184c03b98c809c399e11cb |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T06:01:07Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-d718155f4c184c03b98c809c399e11cb2023-11-22T21:01:54ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-11-0122211204110.3390/ijms222112041Heparin and Derivatives for Advanced Cell TherapiesSandra Laner-Plamberger0Michaela Oeller1Eva Rohde2Katharina Schallmoser3Dirk Strunk4Department of Transfusion Medicine, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Transfusion Medicine, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Transfusion Medicine, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Transfusion Medicine, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaSpinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaHeparin and its derivatives are saving thousands of human lives annually, by successfully preventing and treating thromboembolic events. Although the mode of action during anticoagulation is well studied, their influence on cell behavior is not fully understood as is the risk of bleeding and other side effects. New applications in regenerative medicine have evolved supporting production of cell-based therapeutics or as a substrate for creating functionalized matrices in biotechnology. The currently resurgent interest in heparins is related to the expected combined anti-inflammatory, anti-thrombotic and anti-viral action against COVID-19. Based on a concise summary of key biochemical and clinical data, this review summarizes the impact for manufacturing and application of cell therapeutics and highlights the need for discriminating the different heparins.https://www.mdpi.com/1422-0067/22/21/12041heparincell therapyregenerative medicinebiomaterialshuman platelet lysateextracellular vesicles |
| spellingShingle | Sandra Laner-Plamberger Michaela Oeller Eva Rohde Katharina Schallmoser Dirk Strunk Heparin and Derivatives for Advanced Cell Therapies International Journal of Molecular Sciences heparin cell therapy regenerative medicine biomaterials human platelet lysate extracellular vesicles |
| title | Heparin and Derivatives for Advanced Cell Therapies |
| title_full | Heparin and Derivatives for Advanced Cell Therapies |
| title_fullStr | Heparin and Derivatives for Advanced Cell Therapies |
| title_full_unstemmed | Heparin and Derivatives for Advanced Cell Therapies |
| title_short | Heparin and Derivatives for Advanced Cell Therapies |
| title_sort | heparin and derivatives for advanced cell therapies |
| topic | heparin cell therapy regenerative medicine biomaterials human platelet lysate extracellular vesicles |
| url | https://www.mdpi.com/1422-0067/22/21/12041 |
| work_keys_str_mv | AT sandralanerplamberger heparinandderivativesforadvancedcelltherapies AT michaelaoeller heparinandderivativesforadvancedcelltherapies AT evarohde heparinandderivativesforadvancedcelltherapies AT katharinaschallmoser heparinandderivativesforadvancedcelltherapies AT dirkstrunk heparinandderivativesforadvancedcelltherapies |